Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's ...

While Donald Trump spared pharma companies from his tariff announcement last week, he revealed yesterday plans to announce ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer’s disease (AD), but its role in the brain was unknown until now. In a paper ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...

Amid recent market fluctuations and economic uncertainties, investors are seeking opportunities that can weather the storm. Penny stocks, a term that might seem outdated, continue to hold potential ...

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Regulus (RGLS – Research Report) today and set a price target of $7.00. The ...

Reliv International Inc (RELV) is expected to report for 4Q. Rubicon Technology Inc (RBCN) is expected to report for 4Q. Ryvyl Inc (RVYL) is expected to report $-0.33 for 4Q. SouthGobi Resources Ltd ...

Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an ...

Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.4% following an upgrade from Wells Fargo (NYSE: WFC) ...